UK company CHARM Therapeutics has completed an USD 80 million Series B round led by New Enterprise Associates and SR One with participation from NVIDIA and existing investors, bringing total funding to over USD 150 million. The company, co-founded by Nobel laureate David Baker, will advance its next-generation menin inhibitor for acute myeloid leukemia (AML) into clinical development in early 2026. CHARM's DragonFold platform uses artificial intelligence to design molecules resistant to known clinical mutations that limit first-generation therapies like Syndax's revumenib.

Pre-clinical data shows complete tumour regression at low doses, addressing key limitations of current menin inhibitors including QTc prolongation and drug-drug interactions. The AI-driven approach demonstrates potential for improved safety and durability in targeting the menin-KMT2A protein-protein interaction that drives leukemogenesis in specific AML subtypes. CHARM represents the convergence of computational biology and oncology drug discovery.

PharmCube's NextBiopharm® database shows that CHARM Therapeutics is entering a sector already populated by 29 menin inhibitor developers. Click here to request a free trial for NextBiopharm®.